New lipophilic pro-vitamin C, tetra-isopalmitoyl ascorbic acid (VC-IP), suppresses senile lentigo through controlling of melanocytes-keratinocytes interaction.

No author information is available for this submission.

44 views
0 downloads

Presentation

The authors are in the process of completing this submission.

Please try again later.

Abstract

Senile lentigo are hyperpigmented macules of skin that occur in irregular shapes, appearing most commonly in the sun-exposed areas of the skin such as on the face and back of the hands, and are a common component of photoaged skin. Vitamin C is well known to play an important role in maintaining skin physiology, especially as a skin whitening and blighting agent. We previously demonstrated that a new stable lipophilic pro-vitamin C derivative, tetra-isopalmitoyl ascorbic acid (VC-IP), showed significant suppressive effect for UVB-induced skin pigmentation by conversion into vitamin C in skin tissue. In addition, we reported that VC-IP showed multiple physiological activities represented by scavenging of ROS and reduction of inflammatory cytokines, IL-1α and PGE2, in keratinocytes. In this study, we evaluated that effectiveness of VC-IP on senile lentigo by conducting clinical test approved by the institutional ethical committee. VC-IP significantly improved brightness of aging spot and skin tone to evenness by mechanical measurements. Moreover, self-assessment study demonstrated that subjects were satisfied with the following parameters; appearance of aged spot, skin brightness, fading of dullness or yellowing and zero adverse reaction. Furthermore, we newly identified that VC-IP strongly suppressed the melanin delivery by inhibition of dendrite elongation stimulated by endothelin-1 in melanocytes-keratinocytes co-culture system. There are still many discussions on how senile lentigo represents in skin, however, these results suggested possibility that VC-IP is effective for improving hyperpigmented spot based on controlling of melanocytes-keratinocytes interaction.

Discussion

Ask a Question

Get involved to find out more about this Presentation.

All Comments

Create an Account or Log In to participate in the discussion

Loading discussions